Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634853 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
A Phase 3 study, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
NCT02634853 is a Phase 3 study that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 429 participants.
The verdict
NCT02634853, a Phase 3 study, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
Interventions
- DRUG Placebo Ophthalmic Solution
- DRUG 1% Tavilermide Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634853
The ClinicalTrials.gov registry entry for NCT02634853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 429 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mimetogen Pharmaceuticals USA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Ophthalmic Solution is the first listed.
NCT02634853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634853 about?
NCT02634853 is a clinical study titled "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye". The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
What is the current status of trial NCT02634853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2015-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02634853?
The interventions under investigation include: Placebo Ophthalmic Solution (DRUG), 1% Tavilermide Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02634853?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.